These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23132553)

  • 1. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.
    Danese E; Montagnana M; Johnson JA; Rettie AE; Zambon CF; Lubitz SA; Suarez-Kurtz G; Cavallari LH; Zhao L; Huang M; Nakamura Y; Mushiroda T; Kringen MK; Borgiani P; Ciccacci C; Au NT; Langaee T; Siguret V; Loriot MA; Sagreiya H; Altman RB; Shahin MH; Scott SA; Khalifa SI; Chowbay B; Suriapranata IM; Teichert M; Stricker BH; Taljaard M; Botton MR; Zhang JE; Pirmohamed M; Zhang X; Carlquist JF; Horne BD; Lee MT; Pengo V; Guidi GC; Minuz P; Fava C
    Clin Pharmacol Ther; 2012 Dec; 92(6):746-56. PubMed ID: 23132553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.
    Lacut K; Ayme-Dietrich E; Gourhant L; Poulhazan E; Andro M; Becquemont L; Mottier D; Le Gal G; Verstuyft C
    Br J Clin Pharmacol; 2012 Mar; 73(3):428-36. PubMed ID: 21883387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.
    Biss TT; Avery PJ; Brandão LR; Chalmers EA; Williams MD; Grainger JD; Leathart JB; Hanley JP; Daly AK; Kamali F
    Blood; 2012 Jan; 119(3):868-73. PubMed ID: 22010099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
    Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ
    Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.
    Nakamura K; Obayashi K; Araki T; Aomori T; Fujita Y; Okada Y; Kurabayashi M; Hasegawa A; Ohmori S; Nakamura T; Yamamoto K
    J Clin Pharm Ther; 2012 Aug; 37(4):481-5. PubMed ID: 22172097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.
    Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH
    Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients.
    Pautas E; Moreau C; Gouin-Thibault I; Golmard JL; Mahé I; Legendre C; Taillandier-Hériche E; Durand-Gasselin B; Houllier AM; Verrier P; Beaune P; Loriot MA; Siguret V
    Clin Pharmacol Ther; 2010 Jan; 87(1):57-64. PubMed ID: 19794411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
    Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T
    Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population.
    Djaffar-Jureidini I; Chamseddine N; Keleshian S; Naoufal R; Zahed L; Hakime N
    Genet Test Mol Biomarkers; 2011 Nov; 15(11):827-30. PubMed ID: 21651319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.
    McDonald MG; Rieder MJ; Nakano M; Hsia CK; Rettie AE
    Mol Pharmacol; 2009 Jun; 75(6):1337-46. PubMed ID: 19297519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms of VKORC1, CYP2C9, CYP4F2 in Bai, Tibetan Chinese.
    Zeng WT; Zheng QS; Huang M; Cen HJ; Lai Y; Chen WY; Zhao LZ; Leng XY
    Pharmazie; 2012 Jan; 67(1):69-73. PubMed ID: 22393834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.
    Zhang X; Li L; Ding X; Kaminsky LS
    Drug Metab Dispos; 2011 Aug; 39(8):1433-9. PubMed ID: 21562147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
    Wells PS; Majeed H; Kassem S; Langlois N; Gin B; Clermont J; Taljaard M
    Thromb Res; 2010 Jun; 125(6):e259-64. PubMed ID: 20421126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
    Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F
    Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
    Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
    Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
    Shahin MH; Khalifa SI; Gong Y; Hammad LN; Sallam MT; El Shafey M; Ali SS; Mohamed ME; Langaee T; Johnson JA
    Pharmacogenet Genomics; 2011 Mar; 21(3):130-5. PubMed ID: 21228733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction.
    Carlquist JF; Horne BD; Mower C; Park J; Huntinghouse J; McKinney JT; Muhlestein JB; Anderson JL
    J Thromb Thrombolysis; 2010 Oct; 30(3):358-64. PubMed ID: 20499136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.